Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 126 articles:
HTML format
Text format



Single Articles


    May 2015
  1. WALLINGFORD SC, Iannacone MR, Youlden DR, Baade PD, et al
    Comparison of melanoma incidence and trends among youth under 25 years in Australia and England, 1990-2010.
    Int J Cancer. 2015 May 8. doi: 10.1002/ijc.29598.
    PubMed     Text format     Abstract available


  2. HELGADOTTIR H, Hoiom V, Tuominen R, Jonsson G, et al
    CDKN2A mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Int J Cancer. 2015 May 5. doi: 10.1002/ijc.29595.
    PubMed     Text format     Abstract available


    April 2015
  3. BROSSARD M, Fang S, Vaysse A, Wei Q, et al
    Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk.
    Int J Cancer. 2015 Apr 17. doi: 10.1002/ijc.29570.
    PubMed     Text format     Abstract available


    March 2015
  4. BRAMANTE S, Kaufmann JK, Veckman V, Liikanen I, et al
    Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Int J Cancer. 2015 Mar 26. doi: 10.1002/ijc.29536.
    PubMed     Text format     Abstract available


  5. RIBERO S, Davies JR, Requena C, Carrera C, et al
    High naevus counts confer a favourable prognosis in melanoma patients.
    Int J Cancer. 2015 Mar 21. doi: 10.1002/ijc.29525.
    PubMed     Text format     Abstract available


  6. WANG J, Yu F, Jia X, Iwanowycz S, et al
    MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.
    Int J Cancer. 2015;136:E602-13.
    PubMed     Text format     Abstract available


  7. MAULDIN IS, Wang E, Deacon DH, Olson WC, et al
    TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
    Int J Cancer. 2015 Mar 12. doi: 10.1002/ijc.29515.
    PubMed     Text format     Abstract available


  8. JOSHI S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, et al
    Galpha(13) mediates human cytomegalovirus-encoded chemokine receptor US28 induced cell death in melanoma.
    Int J Cancer. 2015 Mar 6. doi: 10.1002/ijc.29506.
    PubMed     Text format     Abstract available


  9. DOBERSTEIN K, Harter PN, Haberkorn U, Bretz NP, et al
    Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.
    Int J Cancer. 2015;136:E326-39.
    PubMed     Text format     Abstract available


    February 2015
  10. LAUBER S, Wong S, Cutz JC, Tanaka M, et al
    Novel function of Oncostatin M as a potent tumour-promoting agent in lung.
    Int J Cancer. 2015;136:831-43.
    PubMed     Text format     Abstract available


  11. SIURALA M, Bramante S, Vassilev L, Hirvinen M, et al
    Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
    Int J Cancer. 2015;136:945-54.
    PubMed     Text format     Abstract available


  12. SADEGH L, Chen PW, Brown JR, Han Z, et al
    NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.
    Int J Cancer. 2015 Feb 14. doi: 10.1002/ijc.29480.
    PubMed     Text format     Abstract available


    January 2015
  13. JUNG JW, Overgaard NH, Burke MT, Isbel N, et al
    Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
    Int J Cancer. 2015 Jan 22. doi: 10.1002/ijc.29450.
    PubMed     Text format     Abstract available


  14. CHENG M, Ahmed M, Xu H, Cheung NK, et al
    Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Int J Cancer. 2015;136:476-86.
    PubMed     Text format     Abstract available


  15. YUAN H, Liu H, Liu Z, Zhu D, et al
    Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.
    Int J Cancer. 2015 Jan 13. doi: 10.1002/ijc.29429.
    PubMed     Text format     Abstract available


  16. YUE C, Xu J, Tan Estioko MD, Kotredes KP, et al
    Host STAT2/type I interferon axis controls tumor growth.
    Int J Cancer. 2015;136:117-26.
    PubMed     Text format     Abstract available


  17. GEBREMESKEL S, LeVatte T, Liwski RS, Johnston B, et al
    The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.
    Int J Cancer. 2015;136:234-40.
    PubMed     Text format     Abstract available


    December 2014
  18. JOUVE N, Bachelier R, Despoix N, Blin MG, et al
    CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation.
    Int J Cancer. 2014 Dec 2. doi: 10.1002/ijc.29370.
    PubMed     Text format     Abstract available


    November 2014
  19. KVASKOFF M, Pandeya N, Green AC, Perry S, et al
    Solar elastosis and cutaneous melanoma: A site-specific analysis.
    Int J Cancer. 2014 Nov 18. doi: 10.1002/ijc.29335.
    PubMed     Text format     Abstract available


  20. NEWTON-BISHOP JA, Davies JR, Latheef F, Randerson-Moor J, et al
    25-hydroxyvitamin D /D levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort.
    Int J Cancer. 2014 Nov 18. doi: 10.1002/ijc.29334.
    PubMed     Text format     Abstract available


  21. TUOMINEN R, Jewell R, van den Oord JJ, Wolter P, et al
    MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
    Int J Cancer. 2014 Nov 15. doi: 10.1002/ijc.29332.
    PubMed     Text format     Abstract available


  22. TAYLOR NJ, Reiner AS, Begg CB, Cust AE, et al
    Inherited variation at MC1R and ASIP and association with melanoma-specific survival.
    Int J Cancer. 2014 Nov 10. doi: 10.1002/ijc.29317.
    PubMed     Text format     Abstract available


  23. LOUMAGNE L, Baudhuin J, Favier B, Montespan F, et al
    In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance.
    Int J Cancer. 2014;135:2107-17.
    PubMed     Text format     Abstract available


    October 2014
  24. JIANG H, Gebhardt C, Umansky L, Beckhove P, et al
    Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
    Int J Cancer. 2014 Oct 29. doi: 10.1002/ijc.29297.
    PubMed     Text format     Abstract available


  25. OSELLA-ABATE S, Ribero S, Sanlorenzo M, Maule MM, et al
    Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years.
    Int J Cancer. 2014 Oct 21. doi: 10.1002/ijc.29281.
    PubMed     Text format     Abstract available


  26. LAW MH, Rowe C, Montgomery GW, Hayward NK, et al
    PARP1 polymorphisms play opposing roles in melanoma occurrence and survival.
    Int J Cancer. 2014 Oct 21. doi: 10.1002/ijc.29280.
    PubMed     Text format    


  27. IBARROLA-VILLAVA M, Kumar R, Nagore E, Benfodda M, et al
    Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition.
    Int J Cancer. 2014 Oct 10. doi: 10.1002/ijc.29257.
    PubMed     Text format     Abstract available


  28. RUFFINI F, Graziani G, Levati L, Tentori L, et al
    Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of alphavbeta5 integrin.
    Int J Cancer. 2014 Oct 4. doi: 10.1002/ijc.29252.
    PubMed     Text format     Abstract available


    September 2014
  29. KHALKHALI-ELLIS Z, Kirschmann DA, Seftor EA, Gilgur A, et al
    Divergence(s) in Nodal signaling between aggressive melanoma and embryonic stem cells.
    Int J Cancer. 2014 Sep 9. doi: 10.1002/ijc.29198.
    PubMed     Text format     Abstract available


  30. FANG S, Wang Y, Chun YS, Liu H, et al
    The relationship between blood IL-12p40 level and melanoma progression.
    Int J Cancer. 2014 Sep 5. doi: 10.1002/ijc.29182.
    PubMed     Text format     Abstract available


    August 2014
  31. VAN HAUWERMEIREN F, Vandenbroucke RE, Grine L, Puimege L, et al
    Antisense oligonucleotides against TNFR1 prevent toxicity of TNF/IFNgamma treatment in mouse tumor models.
    Int J Cancer. 2014;135:742-50.
    PubMed     Text format     Abstract available


  32. CHEN JL, Dawoodji A, Tarlton A, Gnjatic S, et al
    NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 Fowlpox virus.
    Int J Cancer. 2014 Aug 1. doi: 10.1002/ijc.29118.
    PubMed     Text format     Abstract available


    July 2014
  33. BARRETT JH, Taylor JC, Bright C, Harland M, et al
    Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions.
    Int J Cancer. 2014 Jul 31. doi: 10.1002/ijc.29099.
    PubMed     Text format     Abstract available


  34. IZRAELY S, Sagi-Assif O, Klein A, Meshel T, et al
    The Metastatic Microenvironment: Claudin-1 Suppresses the Malignant Phenotype of Melanoma Brain Metastasis.
    Int J Cancer. 2014 Jul 21. doi: 10.1002/ijc.29090.
    PubMed     Text format     Abstract available


    June 2014
  35. WOLNICKA-GLUBISZ A, Strickland FM, Wielgus A, Anver M, et al
    A melanin-independent interaction between Mc1r and Met signalling pathways is required for HGF-dependent melanoma.
    Int J Cancer. 2014 Jun 28. doi: 10.1002/ijc.29050.
    PubMed     Text format     Abstract available


  36. JAYAWARDANA K, Schramm SJ, Haydu L, Thompson JF, et al
    Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information.
    Int J Cancer. 2014 Jun 27. doi: 10.1002/ijc.29047.
    PubMed     Text format     Abstract available


  37. PASQUALI E, Garcia-Borron JC, Fargnoli MC, Gandini S, et al
    MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: A pooled-analysis from the M-SKIP project.
    Int J Cancer. 2014 Jun 10. doi: 10.1002/ijc.29018.
    PubMed     Text format     Abstract available


  38. ZHONG H, Gutkin DW, Han B, Ma Y, et al
    Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.
    Int J Cancer. 2014;134:2633-45.
    PubMed     Text format     Abstract available


    May 2014
  39. JUNG JI, Cho HJ, Jung YJ, Kwon SH, et al
    High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: Roles of adipocytes and M2-macrophages.
    Int J Cancer. 2014 May 20. doi: 10.1002/ijc.28983.
    PubMed     Text format     Abstract available


  40. ZORNIG I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, et al
    Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Int J Cancer. 2014 May 17. doi: 10.1002/ijc.28980.
    PubMed     Text format     Abstract available


  41. IANNACONE MR, Youlden DR, Baade PD, Aitken JF, et al
    Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia.
    Int J Cancer. 2014 May 8. doi: 10.1002/ijc.28956.
    PubMed     Text format     Abstract available


    April 2014
  42. HOSOI A, Matsushita H, Shimizu K, Fujii S, et al
    Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
    Int J Cancer. 2014;134:1810-22.
    PubMed     Text format     Abstract available


  43. DIHLMANN S, Tao S, Echterdiek F, Herpel E, et al
    Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients.
    Int J Cancer. 2014 Apr 12. doi: 10.1002/ijc.28891.
    PubMed     Text format     Abstract available


    March 2014
  44. XIE L, Yui J, Fujinaga M, Hatori A, et al
    Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe F-FITM.
    Int J Cancer. 2014 Mar 18. doi: 10.1002/ijc.28842.
    PubMed     Text format     Abstract available


  45. JABLONSKA J, Wu CF, Andzinski L, Leschner S, et al
    CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-beta.
    Int J Cancer. 2014;134:1346-58.
    PubMed     Text format     Abstract available


  46. BRAUN J, Strittmatter K, Nubel T, Komljenovic D, et al
    Loss of stromal JUNB does not affect tumor growth and angiogenesis.
    Int J Cancer. 2014;134:1511-6.
    PubMed     Text format     Abstract available


  47. BEETON-KEMPEN N, Duarte J, Shoko A, Serufuri JM, et al
    Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.
    Int J Cancer. 2014 Mar 6. doi: 10.1002/ijc.28832.
    PubMed     Text format     Abstract available


    February 2014
  48. DAVIES JR, Jewell R, Affleck P, Anic GM, et al
    Inherited variation in the PARP1 gene and survival from melanoma.
    Int J Cancer. 2014 Feb 18. doi: 10.1002/ijc.28796.
    PubMed     Text format     Abstract available


  49. WANG Q, Beaumont KA, Otte NJ, Font J, et al
    Targeting glutamine transport to suppress melanoma cell growth.
    Int J Cancer. 2014 Feb 17. doi: 10.1002/ijc.28749.
    PubMed     Text format     Abstract available


  50. MAMLOUK S, Kalucka J, Singh RP, Franke K, et al
    Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
    Int J Cancer. 2014;134:849-58.
    PubMed     Text format     Abstract available


    January 2014
  51. LABAN S, Atanackovic D, Luetkens T, Knecht R, et al
    Simultaneous cytoplasmic and nuclear protein expression of MAGE-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head & neck cancer.
    Int J Cancer. 2014 Jan 31. doi: 10.1002/ijc.28752.
    PubMed     Text format     Abstract available


  52. IWAMOTO H, Ojima T, Hayata K, Katsuda M, et al
    Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs.
    Int J Cancer. 2014;134:332-41.
    PubMed     Text format     Abstract available


    December 2013
  53. DANIEL-MESHULAM I, Horovitz-Fried M, Cohen CJ
    Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.
    Int J Cancer. 2013;133:2903-13.
    PubMed     Text format     Abstract available


    November 2013
  54. BISHOP KD, Olszewski AJ
    Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis.
    Int J Cancer. 2013 Nov 22. doi: 10.1002/ijc.28625.
    PubMed     Text format     Abstract available


  55. FU X, Rivera A, Tao L, Zhang X, et al
    Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery.
    Int J Cancer. 2013;133:2483-92.
    PubMed     Text format     Abstract available


  56. VUONG K, McGeechan K, Armstrong BK, Cust AE, et al
    Occupational sun exposure and risk of melanoma according to anatomical site.
    Int J Cancer. 2013 Nov 13. doi: 10.1002/ijc.28603.
    PubMed     Text format     Abstract available


  57. SMALL DM , Burden RE, Jaworski J, Hegarty SM, et al
    Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization.
    Int J Cancer. 2013;133:2102-12.
    PubMed     Text format     Abstract available


    October 2013
  58. SCHILLING B , Sucker A, Griewank K, Zhao F, et al
    Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.
    Int J Cancer. 2013;133:1653-63.
    PubMed     Text format     Abstract available


  59. WENNERBERG E , Sarhan D, Carlsten M, Kaminskyy VO, et al
    Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
    Int J Cancer. 2013;133:1643-52.
    PubMed     Text format     Abstract available


    August 2013
  60. HATCH SB , Swift LP, Caporali S, Carter R, et al
    XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection.
    Int J Cancer. 2013 Aug 26. doi: 10.1002/ijc.28454.
    PubMed     Text format     Abstract available


  61. BIDARD FC , Madic J, Mariani P, Piperno-Neumann S, et al
    Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
    Int J Cancer. 2013 Aug 12. doi: 10.1002/ijc.28436.
    PubMed     Text format     Abstract available


    July 2013
  62. SALERNO EP , Olson WC, McSkimming C, Shea S, et al
    T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins.
    Int J Cancer. 2013 Jul 20. doi: 10.1002/ijc.28391.
    PubMed     Text format     Abstract available


  63. SFONDRINI L , Sommariva M, Tortoreto M, Meini A, et al
    Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
    Int J Cancer. 2013;133:383-93.
    PubMed     Text format     Abstract available


    June 2013
  64. ZHANG Q , Xu X, Yuan Y, Gong X, et al
    IPS-1 plays a dual function to directly induce apoptosis in murine melanoma cells by inactivated Sendai virus.
    Int J Cancer. 2013 Jun 20. doi: 10.1002/ijc.28340.
    PubMed     Text format     Abstract available


  65. DEL CAMPO AB , Kyte JA, Carretero J, Zinchencko S, et al
    Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
    Int J Cancer. 2013 Jun 20. doi: 10.1002/ijc.28338.
    PubMed     Text format     Abstract available


  66. HUGHES MC , Wright A, Barbour A, Thomas J, et al
    Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome.
    Int J Cancer. 2013 Jun 10. doi: 10.1002/ijc.28318.
    PubMed     Text format     Abstract available


  67. SIEBEN M , Schafer P, Dinsart C, Galle PR, et al
    Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
    Int J Cancer. 2013;132:2548-56.
    PubMed     Text format     Abstract available


    May 2013
  68. BHUTIA SK , Das SK, Azab B, Menezes ME, et al
    Targeting breast cancer initiating/stem cells with melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24).
    Int J Cancer. 2013 May 30. doi: 10.1002/ijc.28289.
    PubMed     Text format     Abstract available


  69. WULFANGER J , Biehl K, Tetzner A, Wild P, et al
    Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma.
    Int J Cancer. 2013 May 17. doi: 10.1002/ijc.28278.
    PubMed     Text format     Abstract available


  70. VOGETSEDER A , Thies S, Ingold B, Roth P, et al
    alphav-Integrin isoform expression in primary human tumors and brain metastases.
    Int J Cancer. 2013 May 10. doi: 10.1002/ijc.28267.
    PubMed     Text format     Abstract available


    April 2013
  71. SURDU S , Fitzgerald EF, Bloom MS, Boscoe FP, et al
    Occupational exposure to arsenic and risk of non-melanoma skin cancer in a multinational European study.
    Int J Cancer. 2013 Apr 18. doi: 10.1002/ijc.28216.
    PubMed     Text format     Abstract available


  72. ANDERSSON K , Luostarinen T, Strand AS, Langseth H, et al
    Prospective study of genital human papillomaviruses and non-melanoma skin cancer.
    Int J Cancer. 2013 Apr 1. doi: 10.1002/ijc.28188.
    PubMed     Text format     Abstract available


    March 2013
  73. KULCSAR G , Gaal D, Kulcsar PI, Schulcz A, et al
    A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
    Int J Cancer. 2013;132:1213-21.
    PubMed     Text format     Abstract available


    February 2013
  74. PASZKOWSKA-SZCZUR K , Scott R, Serrano-Fernandez P, Mirecka A, et al
    Xeroderma pigmentosum genes and melanoma risk.
    Int J Cancer. 2013 Feb 22. doi: 10.1002/ijc.28123.
    PubMed     Text format     Abstract available


  75. DEGOUL F , Borel M, Jacquemot N, Besse S, et al
    In vivo efficacy of melanoma internal radionuclide therapy with a (131) I-labelled melanin-targeting heteroarylcarboxamide molecule.
    Int J Cancer. 2013 Feb 12. doi: 10.1002/ijc.28103.
    PubMed     Text format     Abstract available


  76. ERRICO MC , Felicetti F, Bottero L, Mattia G, et al
    The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway.
    Int J Cancer. 2013 Feb 7. doi: 10.1002/ijc.28097.
    PubMed     Text format     Abstract available


  77. PICKERT G , Lim HY, Weigert A, Haussler A, et al
    Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages.
    Int J Cancer. 2013;132:591-604.
    PubMed     Text format     Abstract available


    January 2013
  78. RAO N , Ke Z, Liu H, Ho CJ, et al
    ADAMTS4 and its proteolytic fragments differentially affect melanoma growth and angiogenesis in mice.
    Int J Cancer. 2013 Jan 15. doi: 10.1002/ijc.28037.
    PubMed     Text format     Abstract available


  79. LEVINE H , Afek A, Shamiss A, Derazne E, et al
    Country of origin, age at migration, and risk of cutaneous melanoma: A migrant cohort study of 1,100,000 israeli men.
    Int J Cancer. 2013 Jan 15. doi: 10.1002/ijc.28031.
    PubMed     Text format     Abstract available


  80. DOS SANTOS SILVA I , De Stavola B, Pizzi C, Evans AD, et al
    Cancer incidence in professional flight crew and air traffic control officers: disentangling the effect of occupational versus lifestyle exposures.
    Int J Cancer. 2013;132:374-84.
    PubMed     Text format     Abstract available


    December 2012
  81. HENRY L , Fabre C, Guiraud I, Bastide S, et al
    Clinical use of p-proteasome in discriminating metastatic melanoma patients: Comparative study with LDH, MIA and S100B protein.
    Int J Cancer. 2012 Dec 12. doi: 10.1002/ijc.27991.
    PubMed     Text format     Abstract available


    November 2012
  82. JEONG HJ , Oh HA, Nam SY, Han NR, et al
    The critical role of mast cell-derived hypoxia-inducible factor-1alpha in human and mice melanoma growth.
    Int J Cancer. 2012 Nov 19. doi: 10.1002/ijc.27937.
    PubMed     Text format     Abstract available


  83. RUSSO V , Pilla L, Lunghi F, Crocchiolo R, et al
    Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
    Int J Cancer. 2012 Nov 13. doi: 10.1002/ijc.27939.
    PubMed     Text format     Abstract available


    September 2012
  84. AUTIER P , Boniol M
    Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom, by F. Elliot and Colleagues, published in the International Journal of Cancer on June 15, 2012.
    Int J Cancer. 2012 Sep 17. doi: 10.1002/ijc.27848.
    PubMed     Text format    


  85. ELLIOTT F , Barrett JH, Bishop DT, Newton-Bishop JA, et al
    Response to P. Autier and M. Boniol regarding our article - Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom.
    Int J Cancer. 2012 Sep 17. doi: 10.1002/ijc.27847.
    PubMed     Text format    


  86. RAAFAT N , Sadowski-Cron C, Mengus C, Heberer M, et al
    Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
    Int J Cancer. 2012;131:E659-69.
    PubMed     Text format     Abstract available


    August 2012
  87. KUCH V , Schreiber C, Thiele W, Umansky V, et al
    Tumor initiating properties of breast cancer and melanoma cells in vivo are not invariably reflected by spheroid formation in vitro, but can be increased by long-term culturing as adherent monolayers.
    Int J Cancer. 2012 Aug 21. doi: 10.1002/ijc.27785.
    PubMed     Text format     Abstract available


  88. LANGONE P , Debata PR, Dolai S, Curcio GM, et al
    Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin.
    Int J Cancer. 2012;131:E569-78.
    PubMed     Text format     Abstract available


  89. KALUZA KM , Thompson JM, Kottke TJ, Flynn Gilmer HC, et al
    Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.
    Int J Cancer. 2012;131:844-54.
    PubMed     Text format     Abstract available


    July 2012
  90. IDORN LW , Thieden E, Philipsen PA, Wulf HC, et al
    Influence of having a home garden on personal UVR exposure behaviour and risk of cutaneous malignant melanoma in Denmark.
    Int J Cancer. 2012 Jul 23. doi: 10.1002/ijc.27734.
    PubMed     Text format     Abstract available


    June 2012
  91. KREISEDER B , Orel L, Bujnow C, Buschek S, et al
    Alpha-catulin down-regulates E-cadherin and promotes melanoma progression and invasion.
    Int J Cancer. 2012 Jun 26. doi: 10.1002/ijc.27698.
    PubMed     Text format     Abstract available


  92. BRUN J , Mahoney DJ, Boeuf FL, Lefebvre C, et al
    Oncolytic vaccinia virus safely and effectively treats skin tumours in mouse models of xeroderma pigmentosum.
    Int J Cancer. 2012 Jun 26. doi: 10.1002/ijc.27695.
    PubMed     Text format     Abstract available


    May 2012
  93. MACCIONI L , Sivaramakrishna Rachakonda P, Scherer D, Bermejo JL, et al
    Variants at chromosome 20 (ASIP locus) and melanoma risk.
    Int J Cancer. 2012 May 24. doi: 10.1002/ijc.27648.
    PubMed     Text format     Abstract available


  94. KRONIG H , Julia Falchner K, Odendahl M, Brackertz B, et al
    PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.
    Int J Cancer. 2012;130:2327-36.
    PubMed     Text format     Abstract available


    April 2012
  95. ERDMANN F , Lortet-Tieulent J, Schuz J, Zeeb H, et al
    International trends in the incidence of malignant melanoma 1953-2008 - are recent generations at higher or lower risk?
    Int J Cancer. 2012 Apr 24. doi: 10.1002/ijc.27616.
    PubMed     Text format     Abstract available


  96. SCHIERER S , Hesse A, Knippertz I, Kaempgen E, et al
    Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
    Int J Cancer. 2012;130:1682-94.
    PubMed     Text format     Abstract available


    March 2012
  97. KLEIN A , Sagi-Assif O, Izraely S, Meshel T, et al
    The metastatic microenvironment. Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain- metastasizing melanoma cells.
    Int J Cancer. 2012 Mar 24. doi: 10.1002/ijc.27552.
    PubMed     Text format     Abstract available


    February 2012
  98. RYU YK , Lee YS, Lee GH, Song KS, et al
    Regulation of glycogen synthase kinase-3 by thymosin beta-4 is associated with gastric cancer cell migration.
    Int J Cancer. 2012 Feb 13. doi: 10.1002/ijc.27490.
    PubMed     Text format     Abstract available


  99. SCHOTT S , Niessner H, Sinnberg T, Venturelli S, et al
    Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanomacells.
    Int J Cancer. 2012 Feb 9. doi: 10.1002/ijc.27476.
    PubMed     Text format     Abstract available


    January 2012
  100. RUGBJERG K , Friis S, Lassen CF, Ritz B, et al
    Malignant melanoma, breast cancer and other cancers in patients with parkinson disease.
    Int J Cancer. 2012 Jan 25. doi: 10.1002/ijc.27443.
    PubMed     Text format     Abstract available


  101. MURAKI C , Ohga N, Hida Y, Nishihara H, et al
    Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.
    Int J Cancer. 2012;130:59-70.
    PubMed     Text format     Abstract available


    November 2011
  102. CUST AE , Goumas C, Holland EA, Agha-Hamilton C, et al
    MC1R genotypes and risk of melanoma before age 40 years: A population-based case-control-family study.
    Int J Cancer. 2011 Nov 18. doi: 10.1002/ijc.27357.
    PubMed     Text format     Abstract available


    October 2011
  103. IZRAELY S , Sagi-Assif O, Klein A, Meshel T, et al
    The metastatic microenvironment. brain residing melanoma metastasis and dormant micro-metastasis.
    Int J Cancer. 2011 Oct 25. doi: 10.1002/ijc.27324.
    PubMed     Text format     Abstract available


  104. SCHAEFER C , Butterfield LH, Lee S, Kim GG, et al
    Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multi-epitope peptide vaccine trial (ECOG 1696).
    Int J Cancer. 2011 Oct 24. doi: 10.1002/ijc.26481.
    PubMed     Text format     Abstract available


  105. CHATTOPADHYAY C , Ellerhorst JA, Ekmekcioglu S, Greene VR, et al
    Association of activated c-Met with NRAS-mutated human melanomas: A possible avenue for targeting.
    Int J Cancer. 2011 Oct 24. doi: 10.1002/ijc.26487.
    PubMed     Text format     Abstract available


  106. BENDER C , Ullrich A
    PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma cell lines.
    Int J Cancer. 2011 Oct 23. doi: 10.1002/ijc.26486.
    PubMed     Text format     Abstract available


    September 2011
  107. CARRETERO R , Wang E, Rodriguez AI, Reinboth J, et al
    Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.
    Int J Cancer. 2011 Sep 30. doi: 10.1002/ijc.26471.
    PubMed     Text format     Abstract available


  108. PICCARD H , Berghmans N, Korpos E, Dillen C, et al
    Glycosaminoglycan mimicry by COAM reduces melanoma growth through chemokine induction and function.
    Int J Cancer. 2011 Sep 27. doi: 10.1002/ijc.26465.
    PubMed     Text format     Abstract available


  109. TANESE K , Grimm EA, Ekmekcioglu S
    The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10.
    Int J Cancer. 2011 Sep 22. doi: 10.1002/ijc.26451.
    PubMed     Text format     Abstract available


  110. GIAMMARIOLI AM , Gambardella L, Barbati C, Pietraforte D, et al
    Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response.
    Int J Cancer. 2011 Sep 12. doi: 10.1002/ijc.26420.
    PubMed     Text format     Abstract available


  111. NIELSEN K , Masback A, Olsson H, Ingvar C, et al
    A prospective, population-based study of 40000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma.
    Int J Cancer. 2011 Sep 2. doi: 10.1002/ijc.26408.
    PubMed     Text format     Abstract available


  112. WAN XM , Zheng F, Zhang L, Miao YY, et al
    Autophagy-mediated chemosensitization by cysteamine in cancer cells.
    Int J Cancer. 2011;129:1087-95.
    PubMed     Text format     Abstract available


    August 2011
  113. TAZZYMAN S , Barry ST, Ashton S, Wood P, et al
    Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
    Int J Cancer. 2011;129:847-58.
    PubMed     Text format     Abstract available


  114. ELLIOTT F , Suppa M, Chan M, Leake S, et al
    Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom.
    Int J Cancer. 2011 Aug 5. doi: 10.1002/ijc.26347.
    PubMed     Text format    


    July 2011
  115. ALCAZAR O , Achberger S, Aldrich W, Hu Z, et al
    Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
    Int J Cancer. 2011 Jul 27. doi: 10.1002/ijc.26320.
    PubMed     Text format     Abstract available


  116. HATIBOGLU MA , Kong LY, Wei J, Wang Y, et al
    The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.
    Int J Cancer. 2011 Jul 25. doi: 10.1002/ijc.26307.
    PubMed     Text format     Abstract available


  117. MUELLER M , Schlosser E, Gander B, Groettrup M, et al
    Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
    Int J Cancer. 2011;129:407-16.
    PubMed     Text format     Abstract available


  118. SPANGLER B , Kappelmann M, Schittek B, Meierjohann S, et al
    ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma.
    Int J Cancer. 2011 Jul 5. doi: 10.1002/ijc.26277.
    PubMed     Text format     Abstract available


    June 2011
  119. LIANG X , Pfeiffer RM, Wheeler W, Maeder D, et al
    Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations.
    Int J Cancer. 2011 Jun 13. doi: 10.1002/ijc.26231.
    PubMed     Text format     Abstract available


  120. TEKLE C , Nygren MK, Chen YW, Dybsjord I, et al
    B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes.
    Int J Cancer. 2011 Jun 13. doi: 10.1002/ijc.26238.
    PubMed     Text format     Abstract available


    May 2011
  121. LUCAS S , van Baren N, de Smet C, Coulie PG, et al
    Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples.
    Int J Cancer. 2011 May 26. doi: 10.1002/ijc.26198.
    PubMed     Text format     Abstract available


    April 2011
  122. MIJATOVIC SA , Timotijevic GS, Miljkovic DM, Radovic JM, et al
    Multiple antimelanoma potential of dry olive leaf extract.
    Int J Cancer. 2011;128:1955-65.
    PubMed     Text format     Abstract available


  123. TROCME E , Mougiakakos D, Johansson CC, All-Eriksson C, et al
    Nuclear HER3 is associated with favourable overall survival in uveal melanoma.
    Int J Cancer. 2011 Apr 11. doi: 10.1002/ijc.26118.
    PubMed     Text format     Abstract available


    March 2011
  124. YERAMIAN A , Sorolla A, Velasco A, Santacana M, et al
    Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitises melanoma cells to Bortezomib by blocking Akt pathway.
    Int J Cancer. 2011 Mar 28. doi: 10.1002/ijc.26096.
    PubMed     Text format     Abstract available


  125. FECCHI K , Travaglione S, Spadaro F, Quattrini A, et al
    Human melanoma cells express FGFR/Src/Rho signaling that entails an adhesion-independent caveolin-1 membrane association.
    Int J Cancer. 2011 Mar 28. doi: 10.1002/ijc.26092.
    PubMed     Text format     Abstract available


    February 2011
  126. MOLHOEK KR , Erdag G, Rasamny J, Murphy C, et al
    VEGFR-2 expression in human melanoma: Revised assessment.
    Int J Cancer. 2011 Feb 3. doi: 10.1002/ijc.25963.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


All AMEDEO services are free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Amedeo is a Flying Publisher website.

   Design: